<DOC>
	<DOCNO>NCT01260155</DOCNO>
	<brief_summary>This study single-center , open-label , randomize , 3-treatment crossover bioavailability study single oral dos E5501 old tablet formulation fast condition new tablet formulation administer fed fasted condition healthy subject .</brief_summary>
	<brief_title>A Single-Center , Open-Label , Randomized , 3-Treatment Crossover Bioavailability Study Single Oral Doses E5501 Old Tablet Formulation Under Fasted Conditions New Tablet Formulation Under Fed Fasted Conditions Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Normal healthy adult male female ( age 1845 year ) Body Mass Index ( BMI ) great equal 18 less equal 32 time Screening All female must negative serum human betachorionic gonadotropin test result negative urine pregnancy test result Screening Baseline . Females childbearing potential must use medically acceptable method contraception throughout entire study period 30 day study drug discontinuation . Postmenopausal woman woman surgically sterilize proven sterile exempt requirement . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation . Male subject abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use , highly effective , method contraception start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day last dose study drug . Willing able comply aspect protocol Provide write informed consent Standard selection criterion typically use protocol Clinically significant abnormal laboratory test result , include platelet count electrolyte abnormality Screening Baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>